



Syngene International Limited

Ref: Syn/CS/SE/PR/December/2019-20/76

Biocon SEZ, Biocon Park, Plot No. 2 &
3, Bommasandra Industrial Area, IV
Phase, Jigani Link Road, Bengaluru
560 099, Karnataka, India

T +91 80 6775 8000

F +91 80 6775 8808

CIN: L85110KA1993PLC01493

www.syngeneintl.com

December 2, 2019

To, The Manager Listing BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager Listing National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Subject: Press Release for appointment of Chief Financial Officer

Please find enclosed the press release announcing the appointment of Mr. Sibaji Biswas as the Chief Financial Officer of the Company. The press release will also be available on website of the Company www.syngeneintl.com.

This is for your information and record.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

Priyadarshini Mahapatra
Company Secretary & Compliance Officer

Syngene to appoint Sibaji Biswas as CFO

December 2, 2019, Bengaluru, India

Syngene International Limited, a leading global contract research organisation, announced the appointment of Mr Sibaji Biswas as Chief Financial Officer and member of the Executive Committee with effect from December 18, 2019. He will succeed Mr M.B. Chinappa, current CFO, who will stay within the Biocon Group of Companies and join Biocon Biologics India Ltd. in a new role.

Sibaji Biswas brings more than twenty years of extensive experience in finance and related functions. His prior experience includes eleven years at Vodafone as well as roles in Fascal Telecommunications, Jhagadia Copper and the ABP Group. In his most recent role, he was CFO and Board Member for Vodafone Romania.

With a B.Tech from IIT Kharagpur, Sibaji is a Chartered Financial Analyst from ICFAI and holds an MBA (Finance) from the University of Calcutta. He has also completed Management Development Programs at the Indian Institute of Management (Ahmedabad) and London Business School.

Jonathan Hunt, CEO, Syngene International said, "We are delighted to welcome Sibaji to Syngene. He brings operational experience combined with a deep finance background which will be extremely valuable to the company as it enters the next phase of growth. We are indebted to Chinappa for the pivotal part he has played in successfully stewarding Syngene through its formative years and in establishing the sound foundations for our continued future growth. The Syngene International Board takes this opportunity to place on record their thanks to Chinappa for the major contribution he has made to the development of the company since 2008 and wishes him every success in his new role."

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), is an innovation focused global discovery, development and manufacturing organisation providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries around the world. Syngene's clientele include world leaders such as Bristol-Myers Squibb, Baxter, Amgen, GSK, Merck KGaA and Herbalife. Its innovative culture is driven by the passion of its 4000-strong team of scientists who work with clients from around the world to solve their scientific problems, improve R&D productivity, speedup time to market and lower the cost of innovation. For more details, visit www.syngeneintl.com.

Syngene

Putting Science to Work

Confidentiality



Quality



Innovation



Science



Contact details

Investor Contact	Media Contact
Chanderlekha Nayar P: +91 80 6775 8821 M: +91 72591 92001 Fax: +91 80 2852 3423 E: chanderlekha.nayar@syngeneintl.com	Sandeep Nair P: +91 80 6775 8775 M: +91 88843 67776 Fax: +91 80 2852 3423 E: sandeep.nair@syngeneintl.com